Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for BioCorRx (BICX) over the last 9 years, with Q3 2025 value amounting to $1.6 million.

  • BioCorRx's Gains from Investment Securities changed N/A to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year change of. This contributed to the annual value of $891443.0 for FY2023, which is 198.9% up from last year.
  • As of Q3 2025, BioCorRx's Gains from Investment Securities stood at $1.6 million.
  • In the past 5 years, BioCorRx's Gains from Investment Securities registered a high of $1.6 million during Q3 2025, and its lowest value of $818631.0 during Q2 2021.
  • Over the past 4 years, BioCorRx's median Gains from Investment Securities value was $858101.0 (recorded in 2022), while the average stood at $1.0 million.
  • As far as peak fluctuations go, BioCorRx's Gains from Investment Securities plummeted by 150.4% in 2021, and later surged by 482.15% in 2022.
  • BioCorRx's Gains from Investment Securities (Quarter) stood at $818631.0 in 2021, then increased by 4.82% to $858101.0 in 2022, then increased by 3.89% to $891443.0 in 2023, then soared by 80.61% to $1.6 million in 2025.
  • Its Gains from Investment Securities was $1.6 million in Q3 2025, compared to $1.5 million in Q2 2025 and $891443.0 in Q3 2023.